Arrowhead Pharmaceuticals, Inc.
ARWR
$21.33
$0.582.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -94.88% | 21,608.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -94.88% | 21,608.36% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -94.88% | 21,608.36% | |||
| SG&A Expenses | 3.64% | 17.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.70% | -1.47% | |||
| Operating Income | -143.43% | 336.17% | |||
| Income Before Tax | -148.45% | 311.07% | |||
| Income Tax Expenses | -124.93% | 1,601.94% | |||
| Earnings from Continuing Operations | -148.56% | 309.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 32.11% | 21.05% | |||
| Net Income | -147.31% | 314.02% | |||
| EBIT | -143.43% | 336.17% | |||
| EBITDA | -141.14% | 347.98% | |||
| EPS Basic | -145.38% | 300.35% | |||
| Normalized Basic EPS | -144.56% | 303.77% | |||
| EPS Diluted | -145.83% | 297.84% | |||
| Normalized Diluted EPS | -144.93% | 302.07% | |||
| Average Basic Shares Outstanding | 4.26% | 6.82% | |||
| Average Diluted Shares Outstanding | 3.39% | 7.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||